Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Techne (TECH) EBITDA Margin (2016 - 2025)

Bio-Techne has reported EBITDA Margin over the past 17 years, most recently at 13.54% for Q4 2025.

  • Quarterly results put EBITDA Margin at 13.54% for Q4 2025, up 1040.0% from a year ago — trailing twelve months through Dec 2025 was 8.59% (down 279.0% YoY), and the annual figure for FY2025 was 7.53%, down 592.0%.
  • EBITDA Margin for Q4 2025 was 13.54% at Bio-Techne, up from 11.75% in the prior quarter.
  • Over the last five years, EBITDA Margin for TECH hit a ceiling of 3647.25% in Q3 2022 and a floor of 1.42% in Q2 2025.
  • Median EBITDA Margin over the past 5 years was 14.86% (2022), compared with a mean of 197.69%.
  • Biggest five-year swings in EBITDA Margin: soared 362293bps in 2022 and later plummeted -363315bps in 2023.
  • Bio-Techne's EBITDA Margin stood at 31.53% in 2021, then fell by -22bps to 24.56% in 2022, then crashed by -38bps to 15.34% in 2023, then tumbled by -80bps to 3.14% in 2024, then skyrocketed by 331bps to 13.54% in 2025.
  • The last three reported values for EBITDA Margin were 13.54% (Q4 2025), 11.75% (Q3 2025), and 1.42% (Q2 2025) per Business Quant data.